Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

249 results about "Tissue specific" patented technology

Tissue Specific Promoters are active in a specific type of cells or tissues such as B cells, monocytic cells, leukocytes, macrophages, muscle, pancreatic acinar cells, endothelial cells, astrocytes, lung...

Vertebral CT image standardization preprocessing method and system fusing multi-parameter features

The invention provides a multi-parameter feature fused vertebral CT image standardization preprocessing method and system. The method comprises the following steps: carrying out initial segmentation on an input original vertebral CT image; carrying out enhancement processing on the image by adopting an anisotropic diffusion filtering algorithm of multi-scale structure perception; establishing a tissue specificity density mapping model of multi-parameter fusion; adopting a self-adaptive segmentation histogram mapping method to map gray distribution of an original image to a standard template; and constructing a rigid-elastic mixed registration model. According to the invention, a complete quality evaluation system is established, the processing quality can be automatically detected and reported, and the reliability of an output result is ensured. By introducing a patient individualized correction mechanism, individual difference information is fully reserved while the standardization effect is ensured, and diagnosis information loss caused by excessive standardization is avoided. The multi-parameter fusion strategy ensures complete reservation of bone tissue density, texture and structure information.
Owner:NANJING WANGSHI INTELLIGENT TECHNOLOGY CO LTD

Construction method of uterine stromal cell specific gene editing mouse

ActiveCN119120466ASolving complex breeding problemsOvercoming the challenge of difficult knockoutHydrolasesMicroinjection basedIntracellularStromal cell
The invention belongs to a molecular biological technology, discloses a construction method of a uterus stromal specific gene editing mouse, and relates to a CRISPR-Cas9-based stromal specific gene editing mouse. The Cre mouse using Vim as a specific promoter activates Cas9, and the Cas9 mouse not only solves the problem of complex breeding of the traditional Cre mouse, but also can realize tissue specific knockout without homozygosis. Cas9 mice can be used for knocking out various sgRNAs, and more possibilities are provided for development of a gene editing model. The obtained Cas9 mouse is mated with an sgMettl3 report mouse, and the Mettl3 gene is successfully knocked out in the uterine stromal cells in a guided manner. The invention provides a valuable gene editing model for endometrial gene research, and overcomes the challenge of difficult knockout of bispecific site mediated genes.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

AAV vector targeting improving method applicable to gene therapy drugs

The invention discloses an AAV vector targeting improvement method applicable to gene therapy drugs, which comprises the following steps: performing high-throughput analysis on target tissue cells through a screening sub-module, screening candidate receptor genes interacting with AAV vector targeting molecules, and determining target receptor genes; the selection submodule is used for designing a gene editing system and selecting a promoter with tissue specific expression to drive the expression of the gene editing system; the introduction submodule is used for introducing the gene editing system into target tissue cells by adopting a gene transfer technology; and the evaluation sub-module is used for selecting the most suitable gene transfer mode according to the characteristics and treatment requirements of the target tissue, and detecting and evaluating the cells subjected to gene editing by utilizing a PCR molecular biological technology. The targeting property of the AAV vector to target tissue cells is improved, the infection of non-target tissues is reduced, and the side effect risk is reduced, so that the gene therapy effect is remarkably improved.
Owner:SUZHOU GEDING BIOTECHNOLOGY CO LTD

Colorectal cancer MRI image segmentation method and system based on multi-dimensional feature fusion

The invention relates to a colorectal cancer MRI image segmentation method and system based on multi-dimensional feature fusion, and relates to the technical field of medical image processing. The method comprises the following steps: firstly, collecting multi-source data of a colorectal cancer patient, preprocessing the data, and constructing a multi-scale feature extraction module to obtain feature data of an image; through a multi-dimensional feature fusion module, features of seven dimensions including texture, shape, gray scale, modal association, life habits, functional metabolism and tissue specificity are integrated, and feature screening and weight distribution are realized in combination with a space-channel attention mechanism; and finally, carrying out feature decoding through a U-Net network, and optimizing a segmentation boundary by adopting a full-connection conditional random field (CRF) of an adaptive potential function. According to the method, multi-modal data integration, multi-scale feature extraction, multi-dimensional feature fusion, attention mechanism enabling, U-Net network decoding and CRF post-processing are combined, so that the accuracy and robustness of colorectal cancer MRI image segmentation are improved.
Owner:CHUZHOU CITY VOCATIONAL COLLEGE

Marker combination, model and method for predicting prognosis risk of colorectal cancer patient

The invention belongs to the technical field of microbiome clinical diagnosis, and particularly relates to a marker combination, a model and a method for predicting the prognosis risk of a colorectal cancer patient. The method comprises the steps of whole genome sequencing data analysis, human source sequence filtering, microorganism sequence extraction and annotation and machine learning diagnosis model construction. The method has the advantages of being high in accuracy and free of culture, tissue-specific microbiota still exist in low-biomass tumors, and promising diagnostic value is shown. A large amount of clinical patient sequencing data can be subjected to secondary development and utilization, the accuracy of tumor diagnosis is improved, and the method can be widely applied to prognosis survival evaluation of patients.
Owner:LANZHOU UNIV

Compositions and Methods for Cell-Specific Expression of Target Genes

Provided are polynucleotides comprising a transcriptional control element comprising a promoter sequence having at least 80% sequence identity to SEQ ID NO: 1. SEQ ID NO:2. SEQ ID NO:3 or SEQ ID NO:4 and a cell- or tissue-specific enhancer element. Also provided are compositions (e.g., vectors, viruses, host cells, and pharmaceutical compositions) comprising said polynucleotides, methods that are useful for expressing a target gene in a host cell, and methods that are useful for expressing a target gene in a subject in need thereof.
Owner:THE TRUSTEES OF PRINCETON UNIV

Matrix-cell co-polymer biological material as well as preparation method and application thereof

The invention relates to the technical field of preparation and application of a co-polymer biological material, and discloses a matrix-cell co-polymer biological material, which comprises a matrix-cell co-polymer, and the matrix-cell co-polymer comprises human decellularized alveolar bone matrix microparticles and human dental sac stem cells. According to the matrix-cell copolymer biological material as well as the preparation method and the application thereof, hDABMPs capable of providing a tissue-specific microenvironment and hDFSCs with development potential are utilized to prepare a developmental bionic matrix-cell copolymer biological material, and the developmental bionic matrix-cell copolymer biological regeneration material has good mechanical strength, good mechanical properties, good biocompatibility, good biocompatibility and good biocompatibility. The stem cell polymer carrying the tissue-specific microenvironment and the developmental potential provides key biological signals of a regeneration scaffold and the specific tissue microenvironment for tissue regeneration so as to support and enhance the regeneration capacity of the implanted stem cell polymer. The strategy highlights the synergistic effect of development guidance and microenvironment induction.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

A modular system to convert therapeutic microrna expression cassettes from polymerase iii-based to polymerase ii-based promoters

PCT designated stage expiredWO2024229211A3DNA/RNA fragmentationExtracellular vesicleA-DNA
Disclosed herein is a modular system, i.e., a DNA expression cassette, specifically designed to convert therapeutic miRNA expression cassettes from the use of ubiquitous RNA polymerase Ill-based promoters to the use of RNA polymerase Il-based promoters to allow for tissue specific expression of the miRNAs while maintaining fidelity and efficacy of processing. Also disclosed herein are compositions, vectors, nanoparticles, extracellular vesicles, and exosomes comprising the nucleic acid expression cassette, as well as methods of use and methods of treatment comprising the DNA expression cassette.
Owner:RES INST AT NATIONWIDE CHILDRENS HOSPITAL

Lipid compounds and compositions for tissue-specific delivery of active substances

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).
Owner:KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY

Methods and compositions for assessing tissue and organ damage

The present disclosure relates to certain compositions, kits, devices, systems and methods, e.g., compositions, kits, devices, systems and methods for assessing methylation status, and / or assessing tissue and / or organ damage or toxicity in a subject. In particular aspects, provided herein are compositions, kits, devices, systems and methods for assessing tissue and / or organ damage or toxicity in a subject based on assessing methylation status of selected one or more tissue-specific or organ-specific target polynucleotide(s), e.g., one or more tissue-specific or organ-specific target genomic DNA sequence(s), from the subject.
Owner:SINGLERA GENOMICS INC

Construction method of uterus specific conditional gene editing mouse based on CRISPR-AsCas12a system

The invention belongs to the technical field of gene editing, and discloses a construction method of a uterus specific conditional gene editing mouse based on a CRISPR-AsCas12a system. According to the invention, the efficient editing ability of AsCas12a is innovatively combined with the uterus tissue specific Pgr promoter. According to the invention, rapid and efficient single gene knockout, such as Ythdf1, Ythdf2 and Ythdf3, is realized in the uterus. The technology breaks through the limitation of long breeding period of the traditional Cre / loxP system, and tissue-specific knockout can be realized without homozygosis. The CRISPR / AsCas12a system provides an animal model for researching pregnancy-related diseases and hormone regulation mechanisms and developing a uterus targeted gene therapy. Reference is provided for exploring other gene editing model animals, and development of gene editing animal models in the veterinary field is broadened.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.
Owner:CHINA PHARM UNIV

Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors by engineered immune cells

Provided herein, among other things, is a cytotoxic immune cell (e.g., a cytotoxic T cell) that expresses an engineered immune receptor (such as a CAR or TCR) whose cytotoxicity within the tumor microenvironment is enhanced by a pro-inflammatory protein that is induced only when the cell binds to either a tissue-specific or cancer-associated antigen. As such, the present cells can be used for the treatment of cancers that are associated with solid tumors.
Owner:RGT UNIV OF CALIFORNIA

Tissue-specific manganese based MRI contrast agents

A tissue-specific manganese based magnetic resonance imaging (MRI) agent includes the formula: wherein T includes at least one cell specific or tissue specific targeting moiety; C includes at least one pyclen based chelating agent complexed with a Mn ion, and L includes at least one optional linker that covalently links the at least one targeting moiety to the at least one chelating agent.
Owner:CASE WESTERN RESERVE UNIV

Methods and system for the reconstruction of drug response and disease networks and uses thereof

Methods comprising an integrated, multiscale artificial intelligence-based system that reconstructs drug-specific pharmacogenomic networks and their constituent functional sub-networks are described. The system uses features of the functional topology of the three-dimensional architecture of drug-modulated spatial contacts in chromatin space. Discovery of a drug pharmacogenomic network is made through the selection of candidate SNPs by imputation, determination of the predicted causality of the SNPs using machine learning and deep learning, use of the causal SNPs to probe the spatial genome as determined by chromosome conformation capture analysis, combining targeted genes controlled by the same cell and tissue-specific enhancers, and reconstruction of the pharmacogenomic network using diverse data sources and metrics based on the results of genome-wide association studies. Knowledge-based segmentation methods are used to deconstruct the pharmacogenomic network into its constituent efficacy and adverse event sub-networks for applications in clinical decision support, drug re-purposing, and in silico drug discovery.
Owner:THE RGT UNIV OF MICHIGAN

Recombinant adeno-associated virus vector carrying TYR gene and application of recombinant adeno-associated virus vector in treatment of OCA1 disease

The invention discloses a recombinant adeno-associated virus vector carrying a TYR gene and application of the recombinant adeno-associated virus vector in treatment of OCA1 diseases. The recombinant adeno-associated virus of the tissue specific expression TYR protein designed by the invention is prepared by co-transfecting HEK293 cells with REP protein of AAV, CAP protein expression plasmids of selected serotypes, helper plasmids and the vector provided by the invention, and packaging; the recombinant adeno-associated virus comprises an expression cassette of a human TYR gene, through suprachoroidal space injection, effective targeted infection of RPE can be realized, and tissue-specific efficient and continuous expression of TYR protein is realized, so that melanin deficiency caused by diseases is improved, retina electrophysiology a and b wave intensity is improved, and the purpose of treating ocular skin albinism I (OCA1) diseases is achieved. The medicine has the characteristic of simple and convenient administration, and is higher in safety and minimum in induced inflammation.
Owner:CHENGDU GENE VECTOR BIOTECHNOLOGY CO LTD

Tissue-specific promoter screening vector and application thereof

The invention discloses a tissue-specific promoter screening vector and application thereof, and relates to the technical field of plant genetic engineering. The screening vector comprises an expression vector and a modified GUS (glucuronidase) reporter gene connected to the expression vector, the modified GUS reporter gene is Cat1muGUS, and the sequence of the Cat1muGUS is shown as SEQ ID NO. 3. According to the present invention, the Cat1muGUS variant is developed based on the Cat1GUS, the Cat1muGUS sensitivity is high, the problem of low dyeing screening efficiency caused by the fact that the Cat1GUS is not sheared in the dicotyledonous plant and the monocotyledonous special tissue can be overcome, in addition, the tissue-specific promoter screening vector is constructed based on the Cat1muGUS variant, and the screening efficiency is high; the method can be well applied to screening of all plant and all tissue specific promoters, and the screening efficiency is improved.
Owner:ANHUI AGRICULTURAL UNIVERSITY

Personalized progenitor cells

Tissue specific progenitor cells generated from pluripotent sources representing endoderm, ectoderm and mesoderm lineages. Progenitor generation can be accomplished by contacting pluripotent stem cells with tissue-specific exosomes, microRNAs, proteins and peptides obtained from stressing said tissue ex vivo. Ex vivo generated tissue organoids which are utilized as sources of "differentiation factors" for the creation of personalized progenitor cells. For generation of pulmonary progenitor cells, decellularized cadaveric lung is populated with allogeneic stem cells to form pulmonary structures, said structures are exposed to various cellular stressors and conditioned media to differentiate pluripotent stem cells into progenitor cells. Extracellular matrix can be obtained from decellularized structures seeded with regenerative cells and used to create organoids that are subjected to stress in order to generate differentiating factors.
Owner:IMMORTA BIO INC

A method for constructing a biological age prediction model based on DNA methylation

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.
Owner:SHENZHEN RAPHA BIOTECHNOLOGY CO LTD

Nucleic acid construct for inducing DDB2 gene silencing and application thereof

PendingCN121294449APlant peptidesRespiratory disorderGenetic interventionsGene silencing
The invention discloses a nucleic acid construct for inducing DDB2 gene silencing and application of the nucleic acid construct. The designed targeted expression system based on the adeno-associated virus (AAV) vector is higher in specificity, non-target tissue can be prevented from being interfered, the tissue specificity of gene intervention is improved, and the off-target risk is small; the shRNA has high stability and processing efficiency, reduces immune response and interference effect, has high expression efficiency and strong histocompatibility, and is suitable for long-term expression intervention in vivo.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Methods and compositions for particulated and reconstituted tissues

Particulated and reconstituted tissues comprising small, densely packed tissue microparticles encapsulated in a tissue specific promoting gel packed at a percolation threshold that can be transplanted into damaged tissue thereby facilitating regeneration following trauma to the tissue. The engineered microparticle construct for tissue replacement and repair, as taught herein, provides numerous benefits including (1) encouraging a regenerative response in damaged tissue regions, (2) mimicking the structural support of native tissue, (3) establishing an environment that promotes attachment, migration, and differentiation of infiltrating stem cells, and (4) providing a source of growth factors and other anti-catabolic growth factors and cytokines. Tissue specific microparticles packed together at, or past, their percolation threshold will provide the necessary mechanical environment and to best recapitulate and integrate with native tissue. The packing of microparticles, derived from the ECM of native tissue to a concentration past the percolation point will yield both the necessary biochemical and biomechanical properties necessary for reconstituting a specific tissue.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO

(Pyridin-2-yl)amine derivatives as TGF-beta R1 (ALK5) inhibitors for the treatment of cancer

The present invention relates to pharmaceutical compounds, compositions, and methods, particularly as they relate to compositions and methods for treating and / or preventing proliferative disorders associated with TGFβR1 activity, such as cancer or fibrosis. The present invention provides compounds of Formula (I) and Formula (II) as further described herein, which have an acidic moiety that enhances tissue specificity to target tissues and organs. The present invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of using these compounds to treat disorders including cancer or fibrosis.
Owner:NEXYS THERAPEUTICS INC

Nerve cryoablation puncture needle kit with nerve stimulation module

The invention discloses a nerve cryoablation puncture needle suite with a nerve stimulation module, and relates to the technical field of medical equipment, the nerve cryoablation puncture needle suite comprises an ultrasonic easy-to-develop puncture needle main body, and the puncture needle main body is connected with a three-way valve; the probe body is connected with the needle body, the delivery pipe is arranged on the surface of the outer end of the needle body, and the other end of the delivery pipe is communicated with the three-way valve and can be used for drug delivery. After the tail end of the needle core is connected with the nerve stimulation module, current can be quantitatively output, the tip of the needle core can stimulate nerve fibers with the diameters from small to large, nerve sensation or movement reaction can be induced, focus-related nervous tissue can be accurately targeted, tissue specificity in the treatment process is ensured, and accuracy and safety of pain treatment are improved. The refrigerating pipe is arranged at the middle end in the needle body, the vacuum cavity is formed in the inner wall of the needle body, when the refrigerating fluid is vaporized and discharged through the outlet, the refrigerating fluid which is not vaporized completely makes contact with the outlet, the filler is cooled and expands to block the outlet, and the refrigerating fluid is effectively prevented from overflowing at low temperature.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Cholesterol derivatives and methods of use

PCT designated stage expiredWO2025014916A1Digestive systemMicroencapsulation basedCholesterol derivativeNanoparticle
Disclosed herein are cholesterol derivatives, and methods of making and using the cholesterol derivatives. Cholesterol derivatives can be utilized in lipid nanoparticles for tissue specific (e.g., spleen) delivery of cargo. Methods of spleen specific delivery of a lipid nanoparticle comprising a cholesterol derivative according to the present invention are also provided.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

AAV vector, vector composition, chimeric vector and method for treating or preventing sma

The present invention relates to an AAV vector comprising a tissue-specific promoter (Syn promoter) for delivering smn1, an AAV vector composition for delivering smn1, an AAV chimeric vector for delivering smn1, and a method for treating or preventing a disease related to SMN deficiency by using same. The provided method for treating or preventing a disease related to SMN deficiency comprises administering the AAV vector, the AAV vector composition and the AAV chimeric vector for delivering smn1 to a subject via two or more administration routes.
Owner:NIKETHERAPEUTICS (HANGZHOU) CO LTD

AAV-based PDE6b viral vector for treating retinitis pigmentosa containing tissue-specifically expressed PDE6a promoter, and use thereof

The present invention relates to: an AAV-based PDE6B viral vector for treating retinitis pigmentosa, the AAV-based PDE6B viral vector containing a tissue-specifically expressed PDE6A promoter; and a use of thereof, and provides a gene therapy for treating retinitis pigmentosa caused by PDE6B gene deficiency. The in vivo therapeutic efficacy of seven types of AAV5-PDE6B vectors was confirmed using an AAV by using a PDE6A promoter that is tissue-specifically expressed in photoreceptor rod cells that develop retinitis pigmentosa. An AAV5-PDE6A-450-PDE6B vector was selected as a candidate due to exhibiting strong tissue-specific expression in photoreceptor rod cells under even off-target conditions, unlike the gene expression characteristics of an AAV5-CMV-PDE6B vector, and was tested so as to be usable in the development of a gene therapeutic agent for treating PDE6B-deficient retinitis pigmentosa patients. Therefore, the present invention, related to AAV5-PDE6B for retinitis pigmentosa treatment and containing a tissue-specifically expressed PDE6A promoter, provides retinitis pigmentosa patients with an important treatment option having improved safety, and can be expected to have fundamental therapeutic effects compared to conventional treatments.
Owner:CDMOGEN CO LTD